FDA Approves Ibrutinib for CLL

Share this article:
New Drug Approved for Refractory or Relapsed Mantle Cell Lymphoma
New Drug Approved for Refractory or Relapsed Mantle Cell Lymphoma

The United States Food and Drug Administration (FDA) today announced its approval of ibrutinib (Imbruvica®) for treatment of chronic lymphocytic leukemia (CLL) in patients who have received at least one prior therapy, according to a press release.

The FDA's decision expands the indication for ibrutinib, which received accelerated approval from the FDA in November 2013 to treat patients with mantle cell lymphoma who have received at least one prior therapy.

Similarly, for the CLL indication, ibrutinib was granted priority review and orphan-product designation.

RELATED: Ibrutinib: Second FDA-Approved Drug with Breakthrough Therapy Designation for MCL

The FDA based their accelerated approval of ibrutinib for CLL on results of a clinical study involving 48 participants who had previously received an average of four therapies and were diagnosed an average of 6.7 years before study enrollment. Researchers administered 420 mg of ibrutinib orally until unacceptable toxicity occurred or until the disease progressed.

According to the release, the cancer shrunk in 58% of participants after treatment, and duration of response ranged from 5.6 to 24.2 months; however, results did not firmly establish a correlation between treatment and improvement in survival or disease-related symptoms.

RELATED: Hematologic Cancers Resource Center

Common side effects of ibrutinib included thrombocytopenia, diarrhea, bruising, neutropenia, anemia, upper respiratory infection, musculoskeletal pain, rash, pyrexia, constipation, peripheral edema, arthralgia, nausea, stomatitis, sinusitis, and dizziness.

“Today's approval provides an important new treatment option for [patients with CLL] whose cancer has progressed despite having undergone previous therapy,” Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in the release. “The FDA completed its review of Imbruvica's new indication under the agency's accelerated approval process, which played a vital role in rapidly making this new therapy available to those who need it most.”

Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Hematologic Cancers

Arzerra Plus Chlorambucil Gets FDA Nod

Arzerra Plus Chlorambucil Gets FDA Nod

The FDA has approved a new indication for Arzerra to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia.

Volasertib Designated Orphan Drug for AML

Volasertib Designated Orphan Drug for AML

The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).

sNDA Submitted for Imbruvica

sNDA Submitted for Imbruvica

Janssen R&D and Pharmacyclics announced the submission of a supplemental New Drug Application for Imbruvica (ibrutinib) for relapsed or refractory chronic lymphocytic leukemia.